ArticleFrontiers in medicine2026
Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the experience of using olokizumab (OKZ) in patients with polymyalgia rheumatica (PMR) who have contraindications or an inadequate response to methotrexate and require steroid-sparing therapy, and to analyze treatment outcomes in this cohort. Methods: A case series included 23 patients with PMR [including giant-cell arteritis (GCA) in 9 patients] treated with OKZ. The assessment of disease activity was carried out using the PMR-activity score (AS) index, as well as laboratory parameters [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. The statistical analysis was performed using the StatTech v program. 4.7.3. Results: Olokizumab therapy resulted in a significant decrease in PMR activity: the PMR-AS index decreased from 18.6 (14.2-24.4) to 3.01 (1.62-6.09) points by 12-24th weeks. Most patients (86.3%) who received therapy achieved remission or low disease activity. Laboratory parameters have also improved: ESR values decreased from 32.00 (20.00-47.00) to 7.00 (5.00-8.50) mm/h, and CRP - from 14.10 (8.10-40.80) to 0.85 (0.30-2.15) mg/l. The steroid dose decreased from 7.5 (5.0-15.0) to 2.50 (0.00-2.50) mg/day by week 24. The results listed above were statistically significant ( Conclusion: Olokizumab demonstrated high efficacy in reducing the activity of PMR, laboratory markers of inflammation and the dose of steroids in patients with inefficacy or intolerance to methotrexate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.